The Greater Boston life sciences sector is experiencing a significant oversupply crisis with 17 million square feet of available lab space and a vacancy rate near 30%, driven by speculative construction amid dwindling demand and a slowdown in venture capital investment. First-half 2025 biotech funding in Boston stalled at $3.3 billion with reduced IPO activity, contributing to reduced real estate absorption and shrinking footprints, especially among early-stage companies. These market headwinds reflect broader investor caution and regulatory uncertainties challenging the biotech ecosystem.